Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42695 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Marco Gattorno und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Giannina Gaslini Institute, Genoa, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Fever, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.
Abstract (Originalsprache)
Objective
We aimed at assessing efficacy, safety, and tolerability of canakinumab in patients with tumor necrosis factor receptor–associated periodic syndrome (TRAPS) during a 72‐week long‐term, open‐label extension of the CLUSTER study.
Methods
Patients received open‐label canakinumab 150 or 300 mg, either every 4 weeks (q4w) or every 8 weeks, with up‐titration permitted after on‐treatment flares (maximum dose: 300 mg q4w). Efficacy assessments included physician global assessment of disease activity, number of flares, and serum C‐reactive protein (CRP) and serum amyloid A protein (SAA) levels. Adverse events were also reported. Results are described for the overall population and according to the cumulative dose of canakinumab adjusted for body weight (94% of patients achieved no or minimal disease activity. Most patients had either no (69.8%) or one flare (24.5%), whereas at baseline, the median number of flares was 9.0 per year. Median CRP levels remained at
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IRCCS Giannina Gaslini Institute, Genoa, Italy.
- IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
- La Fe University and Polytechnic Hospital, Valencia, Spain.
- Charité Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum, Berlin, Germany.
- Alberta Children's Hospital, University of Calgary, Alberta, Canada.
- Novartis Pharma AG, Basel, Switzerland.
ORCID-Profile: Marco Gattorno, Fabrizio De Benedetti
Förderung
- Novartis Pharma AG
Zitieren
APA
Gattorno, M., Obici, L., Penadés, I. C., Kallinich, T., Benseler, S., Dekker, E., Lévy, J., De Benedetti, F., & Lachmann, H. (2024). Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.42695
Vancouver
Gattorno M, Obici L, Penadés IC, Kallinich T, Benseler S, Dekker E, et al. Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis & Rheumatology. 2024. doi:10.1002/art.42695
BibTeX
@article{Gattorno2024,
author = {Gattorno, Marco and Obici, Laura and Penadés, Inmaculada Calvo and Kallinich, Tilmann and Benseler, Susanne and Dekker, Elise and Lévy, Jérémy and De Benedetti, Fabrizio and Lachmann, Helen},
title = {Long‐Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42695}
}
EUVIMED